BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 21, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prolia denosumab regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending the use of Prolia denosumab from Amgen for the primary and secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures for whom...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >